Journal of Investigative Medicine最新文献_第7页

Hydrogen sulfide inhibits early development of atherosclerosis by modulating macrophage uptake of oxidized lipoproteins. EXPRESSS：硫化氢通过调节巨噬细胞对氧化脂蛋白的摄取抑制动脉粥样硬化的早期发展。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-09-26 DOI: 10.1177/10815589241279599

Nan Dong, Gang Yang, Yanmei Liu, Kaiyun Wu

{"title":"Hydrogen sulfide inhibits early development of atherosclerosis by modulating macrophage uptake of oxidized lipoproteins.","authors":"Nan Dong, Gang Yang, Yanmei Liu, Kaiyun Wu","doi":"10.1177/10815589241279599","DOIUrl":"10.1177/10815589241279599","url":null,"abstract":"Atherosclerosis, a major cause of cardiovascular diseases, is characterized by the accumulation of oxidized lipoproteins (ox-LDL) within arterial walls, leading to inflammation and plaque formation. Hydrogen sulfide (H2S) has demonstrated anti-inflammatory and vascular protective properties, but its role in modulating macrophage endocytosis of ox-LDL and its impact on early atherosclerosis development remains unclear. Macrophage cultures were utilized for ox-LDL uptake experiments. Macrophages were pretreated with sodium hydrosulfide (NaHS) (50 μmol/L) or propargylglycine (PPG, 3 mmol/L) for 1 h, followed by incubation with DiI-ox-LDL (10 μg/mL) for an additional 2 h. DiI-ox-LDL uptake was visualized using live-cell imaging. The expression of scavenger receptors CD36 and SR-A was assessed through immunofluorescent staining and western blot analysis. To determine the intracellular signal transduction pathways involved, macrophages were pretreated with NF-κB pathway blocker pyrrolidine dithiocarbamate or MAPK inhibitor PD98059 before the addition of NaHS. NaHS significantly inhibited ox-LDL uptake by macrophages, while PPG treatment markedly increased this process. Immunocytochemistry and western blot analysis revealed that the expressions of CD36 and SR-A were induced by ox-LDL but inhibited by NaHS in a concentration- and time-dependent manner. Furthermore, H2S down-regulated ox-LDL receptors CD36 and SR-A through the NF-κB signal pathway. H2S inhibits early atherosclerosis development by modulating macrophage uptake of ox-LDL through the down-regulation of CD36 and SR-A receptors via the NF-κB signaling pathway. These findings provide new evidence for the role of H2S in atherosclerosis and its potential therapeutic value.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"947-955"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Families with multiple individuals with acute leukemia in their pedigrees. 快讯血统中有多人患急性白血病的家族。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-19 DOI: 10.1177/10815589241262735

Peter H Wiernik, Matthew P Blakley, Janice P Dutcher

{"title":"Families with multiple individuals with acute leukemia in their pedigrees.","authors":"Peter H Wiernik, Matthew P Blakley, Janice P Dutcher","doi":"10.1177/10815589241262735","DOIUrl":"10.1177/10815589241262735","url":null,"abstract":"Forty-one families with multiple cases of de novo acute myeloid leukemia (AML), B-cell acute lymphocytic leukemia (B-ALL), or both are presented. The families were randomly collected from physicians, genetic counselors, and other sources. Medical records were collected and reviewed for all families. In 17 of the families, a parent and child with acute leukemia were identified; and in 15 of the pairs, the parent and child were of the same sex. Nine grandparent-grandchild affected pairs with AML-AML were identified, occurring in six families, and six of those pairs were also of the same sex. Anticipation was a common feature of these multigenerational pairs. Twenty families were identified with multiple siblings (none twins) with acute leukemia. This includes 16 sibling pairs and 4 sibling triples. The members of each sibling pair in the AML-AML group and in the B-ALL-B-ALL group were generally of roughly the same age. Curiously, this is not true of those in the AML-B-ALL group. Four of the 41 families had contributions to more than 1 family relationship category. Although inheritance in familial acute leukemia has usually been consistent with an autosomal dominant pattern, these data suggest that an X chromosome gene may be involved in some cases, perhaps in the pseudoautosomal region of the X chromosome as we have reported in familial Hodgkin lymphoma.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"842-847"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Randomized clinical trials and related concepts in clinical research. 快讯：随机临床试验和临床研究中的相关概念。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-12 DOI: 10.1177/10815589241270464

Rita Nogueiras-Álvarez

引用次数: 0

The effect of pre-hospital use of RAS inhibitors on COVID-19 mortality. EXPRESS：院前使用 RAS 抑制剂对 COVID-19 死亡率的影响。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-28 DOI: 10.1177/10815589241270417

Rama Ibrahim

{"title":"The effect of pre-hospital use of RAS inhibitors on COVID-19 mortality.","authors":"Rama Ibrahim","doi":"10.1177/10815589241270417","DOIUrl":"10.1177/10815589241270417","url":null,"abstract":"The effect of pre-hospital use of renin-angiotensin system (RAS) inhibitors (angiotensin-converting enzyme inhibitors (ACEis)/angiotensin receptor blockers (ARBs)) on clinical outcomes of hypertensive patients with COVID-19 has been questioned due to conflicting reports on this issue. After applying exclusion criteria, 175 COVID-19 hospitalized patients admitted to the Tishreen Hospital from January 1 to July 31, 2021 were retrospectively enrolled in this study. Baseline characteristics and in-hospital mortality rate were assessed between hypertensive (N = 91, 52%) and non-hypertensive (N = 84, 48%) patients, as well as between patients taking ACEis/ARBs and non-ACEis/ARBs within the hypertensive group. A lower mortality rate (51.2 versus 31.9%, p = 0.009) was observed in the hypertensive group (mean age 64.6 years, 64.8% males) compared to the non-hypertensive (mean age 62.6 years, 66.7% males). Patients' mortality in the non-hypertensive group was associated with lower blood oxygen saturation (SPO2 = 75 versus 86%, p = 0.002), increased levels of inflammatory (CRP, white blood cell and neutrophils count), and tissue/renal injury markers (LDH, urea, and creatinine). In the hypertensive group, a lower mortality rate was noted in the ACEis/ARBs group compared to the non-ACEis/ARBs (24.1 versus 45.5%, p = 0.036), and this was associated with a decrease in D-DIMER levels, although not significant (1723 versus 2683 ng/mL, p > 0.05). Death in the non-ACEis/ARBs group was associated with decreased SPO2 and tissue/renal injury markers (LDH, CK, AST, urea, and creatinine). We concluded that hypertension is not a direct cause of poor prognosis in COVID-19 patients and that multi-organ damage is a significant indicator of death from COVID-19. RAS inhibitors could improve the survival of hypertensive COVID-19 patients.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"863-875"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in research on renal injury in paroxysmal nocturnal hemoglobinuria. 夜间阵发性肾损伤的研究进展

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-28 DOI: 10.1177/10815589241254046

Liyan Li, Rong Fu

引用次数: 0

Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population. 表达：胰高血糖素样肽-1 受体激动剂疗法对基层诊所人群血糖控制和体重的影响。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-12 DOI: 10.1177/10815589241270427

Eric J Palecek, Margaret M Kimzey, Jingwen Zhang, Justin Marsden, Chloe Bays, William P Moran, Patrick D Mauldin, Andrew D Schreiner

{"title":"Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population.","authors":"Eric J Palecek, Margaret M Kimzey, Jingwen Zhang, Justin Marsden, Chloe Bays, William P Moran, Patrick D Mauldin, Andrew D Schreiner","doi":"10.1177/10815589241270427","DOIUrl":"10.1177/10815589241270427","url":null,"abstract":"Glucagon-like peptide-1 receptor agonist (GLP-1a) medications have been shown in randomized controlled trials (RCTs) to have consistent and impressive effectiveness in lowering hemoglobin A1c (HbA1c) and weight, but limited data exist on the efficacy of GLP-1a medications in clinical practice. We studied the association between GLP-1a therapy and changes in weight and HbA1c in a real-world patient population. In this retrospective cohort study of patients seen in a primary care clinic between 2012 and 2021, we examined the change in weight and HbA1c over 12 months in a cohort of patients with at least one prescription for a GLP-1a. Within this cohort, treatment was defined as having ≥2 GLP-1a prescriptions at a therapeutic dosage separated by ≥10 months. The cohort included 693 patients of whom 393 (57%) were treated with GLP-1a therapy. The treatment group had a mean change in body mass index (BMI) of -0.83 kg/m2 (±2.88) compared to -0.70 kg/m2 (±2.99) in the without GLP-1a group (p = 0.57). Treated patients had a mean change in HbA1c of -1.00% (±2.07) compared to -0.83% (±1.92) in the without GLP-1a group (p = 0.27). For treated and without GLP-1a patients, respectively, the proportion of patients with a decrease in BMI was 65 versus 64% (p = 0.86), and the proportion with a decrease in HbA1c was 73 versus 69% (p = 0.28). In clinical practice, GLP-1a therapy was associated with more modest reductions in weight and HbA1c than shown in prior RCTs. As GLP-1a use continues to expand throughout primary care, the real-world impact of this pharmacotherapy will require further evaluation.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"911-919"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of Fusobacterium nucleatum in the pathogenesis of colon cancer. 快讯：Fusobacterium nucleatum 在结肠癌发病机制中的作用。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-09-18 DOI: 10.1177/10815589241277829

Bo-Young Hong, Ajay Chhaya, Alejandro Robles, Jorge Cervantes, Sangeeta Tiwari

引用次数: 0

Antimicrobial management in patients undergoing therapeutic plasma exchange: A Cross-Sectional Nationwide Survey. 快讯：治疗性血浆置换患者的抗菌管理：全国横断面调查。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-13 DOI: 10.1177/10815589241270414

Ugur Balaban, Emre Kara, Asli Pinar, Osman Ilhami Ozcebe, Kutay Demirkan, Serhat Unal

{"title":"Antimicrobial management in patients undergoing therapeutic plasma exchange: A Cross-Sectional Nationwide Survey.","authors":"Ugur Balaban, Emre Kara, Asli Pinar, Osman Ilhami Ozcebe, Kutay Demirkan, Serhat Unal","doi":"10.1177/10815589241270414","DOIUrl":"10.1177/10815589241270414","url":null,"abstract":"There is little evidence of antimicrobial elimination via therapeutic plasma exchange (TPE) and no guidelines for antimicrobial optimal dosing in patients undergoing TPE. We aimed to assess current practices and knowledge regarding antimicrobial management during TPE. A structured online survey was conducted from May to November 2023, and physicians were invited to participate through national scientific platforms and professional societies. One hundred five participants completed the survey, of whom 61% were infectious disease physicians, with 68.6% having more than 10 years of experience. That the TPE procedure could significantly affect plasma concentrations of antimicrobial agents was reported by 74.3% of the respondents. Among the physicians, 42.9% suggest antimicrobial dose adjustment, and 38.1% recommend temporarily discontinuing antimicrobial drug administration during TPE. Therapeutic drug monitoring was recommended by 33.3% of the respondents for certain antimicrobials, mainly glycopeptides and aminoglycosides, in patients undergoing concurrent TPE. Furthermore, 59.3% of physicians sometimes consult with another healthcare professional for treatment management, most commonly a pharmacist or a clinical pharmacist and an infectious diseases specialist. The core questions regarding potential drug-, procedure-, and patient-related antimicrobial elimination factors via TPE were responded to accurately by less than half of the physicians. It was clear that they had a lack of clinical practices and knowledge regarding antimicrobial management during TPE. To ensure the therapeutic efficacy of antimicrobials and avoid treatment failure, physicians should improve their practice strategies and consider antimicrobial elimination factors with TPE in this data-poor setting.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"920-929"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of VDR and TLR2 gene variants on the clinical course of patients with COVID-19 disease. 表达：VDR 和 TLR2 基因变异对 COVID-19 疾病患者临床病程的影响。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-19 DOI: 10.1177/10815589241270418

Nilufer Kuruca, Aynur Atilla, Muhammed Taha Kaya, Sedat Gokmen, Ayse Feyda Nursal, Ozgur Kilic, Tuba Kuruoglu, Fatih Temocin, Tolga Guvenc, Serbulent Yigit, Dilek Guvenc

{"title":"Effect of VDR and TLR2 gene variants on the clinical course of patients with COVID-19 disease.","authors":"Nilufer Kuruca, Aynur Atilla, Muhammed Taha Kaya, Sedat Gokmen, Ayse Feyda Nursal, Ozgur Kilic, Tuba Kuruoglu, Fatih Temocin, Tolga Guvenc, Serbulent Yigit, Dilek Guvenc","doi":"10.1177/10815589241270418","DOIUrl":"10.1177/10815589241270418","url":null,"abstract":"The coronavirus disease 2019 (COVID-19) pandemic, which has caused a major global health crisis, primarily targets the upper and lower respiratory tract. But infected individuals may experience different clinical symptoms, ranging from asymptomatic to critical. The vitamin D receptor (VDR) and Toll-like receptor 2 (TLR2) polymorphisms play a role in the immune response. This study aimed to evaluate the effect of VDR Bsml (rs1544410) and TLR2 23bp indel variants on the clinical status of Turkish patients with COVID-19 disease. A total of 312 people, including 106 intensive care unit (ICU) patients, 103 symptomatic hospitalized patients, and 103 healthy controls, were included in the study. The VDR BsmI and TLR2 23bp indel were genotyped using polymerase chain reaction and/or restriction fragment length fraction methods. The VDR BsmI b/b genotype and b allele were higher in symptomatic patients compared to the healthy control group (p = 0.035). The VDR BsmI B/B and B/b genotype distribution did not differ between ICU patients and both symptomatic patients and controls (p > 0.05). We found that B/B:B/b+b/b and B/B+B/b:b/b were significantly different in symptomatic patients compared to controls (p = 0.033 and p = 0.041, respectively). The VDR BsmI b/b genotype distribution was found to be lower in deceased patients than in living patients (p = 0.023). There was no significant difference between the groups in terms of TLR2 23bp indel genotype and allele distribution (p > 0.05). Our study results suggest that the VDR BsmI b allele may have a role in COVID-19 patients with symptomatic findings. These data need to be repeated in different ethnic and larger sample groups.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"876-882"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Iron and cardiovascular health: A review. 快讯铁与心血管健康：综述。

IF 2.5 4区医学

Journal of Investigative Medicine Pub Date : 2024-12-01 Epub Date: 2024-08-12 DOI: 10.1177/10815589241268462

Diana Othon-Martínez, Osiris A Fernandez-Betances, Bárbara X Málaga-Espinoza, Maria E Torres-Perez, Everardo Cobos, Cesar Gutierrez-Martinez

{"title":"Iron and cardiovascular health: A review.","authors":"Diana Othon-Martínez, Osiris A Fernandez-Betances, Bárbara X Málaga-Espinoza, Maria E Torres-Perez, Everardo Cobos, Cesar Gutierrez-Martinez","doi":"10.1177/10815589241268462","DOIUrl":"10.1177/10815589241268462","url":null,"abstract":"Iron is an essential element for the biological processes of living organisms, including the production of crucial oxygen-carrying proteins, formation of heme enzymes, and playing roles in electron transfer and oxidation-reduction reactions. It plays a significant role in various cardiovascular functions, including bioenergetics, electrical activity, and programmed cell death. Minor deficiencies of iron have been found to have negative impact on cardiovascular function in patients with heart failure (HF). The contractility of human cardiomyocytes is impaired by iron deficiency (ID), which results in reduced mitochondrial function and lower energy production, ultimately leading to cardiac function impairment, contributing to significant morbidity and mortality in patients with HF. This review discusses iron homeostasis within the human body, as well as ID pathophysiology and its role in HF. Focusing on therapeutic approaches including iron supplementation and/or repletion in patients with ID and HF, comparing results from recent clinical trials. Intravenous (IV) iron therapy has shown promising results in treating ID in HF patients. Large, randomized trials and meta-analysis, like Ferinject Assessment in patients with ID and chronic HF, AFFIRM-AHF, IRONMAN, and HEART-FID have demonstrated the efficacy of IV iron supplementation with IV ferric carboxymaltose or IV ferric derisomaltose in reducing hospitalizations and improving quality of life in patients with Heart Failure with reduced ejection fraction (HFrEF), New York Heart Association (NYHA) II-III. However, survival and mortality have demonstrated no improvement during acute exacerbations of HF or in outpatient management. The potential benefits of IV iron across the entire HF spectrum and its interaction with other HF therapies remain areas of interest for further research.","PeriodicalId":16112,"journal":{"name":"Journal of Investigative Medicine","volume":" ","pages":"787-797"},"PeriodicalIF":2.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141792669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0